Computerized detection of adverse drug reactions in the medical intensive care unit

International Journal of Medical Informatics

Volumn 80, Issue 8, 2011, Pages 570-578

  Kane Gill, Sandra L ^a,b,c   Visweswaran, Shyam ^a,c   Saul, Melissa I ^c   Wong, An Kwok Ian ^a,c   Penrod, Louis E ^c   Handler, Steven M ^c,d,e  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e VAPHS   (United States)

Author keywords

Adverse drug event; Adverse drug reaction reporting systems; Clinical; Critical care; Decision support systems; Drug toxicity; Information systems; Intensive care units; Safety

Indexed keywords

ADVERSE DRUG EVENT; ADVERSE DRUG REACTIONS; CLINICAL; CRITICAL CARE; DECISION SUPPORTS; DRUG TOXICITY; INTENSIVE CARE;

ARTIFICIAL INTELLIGENCE; BLOOD; DECISION SUPPORT SYSTEMS; GLUCOSE; INTENSIVE CARE UNITS; MEDICAL COMPUTING; METABOLISM; MONITORING; SIGNAL DETECTION; SODIUM; UREA;

PHARMACODYNAMICS;

GLUCOSE; QUINIDINE; SODIUM; VANCOMYCIN;

ADULT; ADVERSE DRUG REACTION; ARTICLE; CALCULATION; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL ASSESSMENT TOOL; CLINICAL EVENT MONITOR; CLINICAL TRIAL; COMPUTER ASSISTED DIAGNOSIS; DRUG BLOOD LEVEL; DRUG MONITORING; FEMALE; HUMAN; HYPOGLYCEMIA; HYPONATREMIA; INTENSIVE CARE UNIT; MALE; PATIENT MONITORING; PATIENT SAFETY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIGNAL DETECTION; UREA NITROGEN BLOOD LEVEL;

ADULT; DRUG TOXICITY; HUMANS; INTENSIVE CARE UNITS; PENNSYLVANIA; PROSPECTIVE STUDIES;

EID: 79960069551     PISSN: 13865056     EISSN: 18728243     Source Type: Journal    
DOI: 10.1016/j.ijmedinf.2011.04.005     Document Type: Article

References (58)

1. Elixhauser A., Owens P. Statistical Brief #29: Adverse Drug Events in U.S. Hospitals, 2004 2007, Agency for Healthcare Research and Quality.
2. Lazarou J., Pomeranz B.H., Corey P.N. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998, 279:1200-1205.
3. Bates D., Spell N., Cullen D.J., Burdick E., Laird N., Petersen L.A., et al. The costs of adverse drug events in hospitalized patients. JAMA 1997, 277:307-311.
4. Wilmer A., Louie K., Dodek P., Wong H., Ayas N. Incidence of medication errors and adverse drug events in the ICU: a systematic review. Qual. Saf. Health Care 2010, 19:e7.
5. Cullen D.J., Sweitzer B.J., Bates D.W., Burdick E., Edmondson A., Leape L.L. Preventable adverse drug events in hospitalized patients: a comparative study of intensive care and general care units. Crit. Care Med. 1997, 25:1289-1297.
6. Kane-Gill S.L., Devlin J.W. Adverse drug event reporting in intensive care units: a survey of current practices. Ann. Pharmacother. 2006, 40:1267-1273.
7. Institute of Medicine Preventing Medication Errors 2007, National Academies Press, Washington, DC.
8. Hripcsak G., Clayton P.D., Jenders R.A., Cimino J.J., Johnson S.B. Design of a clinical event monitor. Comput. Biomed. Res. 1996, 29:194-221.
9. Levy M., Azaz-Livshits T., Sadan B., Shalit M., Geisslinger G., Brune K. Computerized surveillance of adverse drug reactions in hospital: implementation. Eur. J. Clin. Pharmacol. 1999, 54:887-892.
10. Murff H.J., Patel V.L., Hripcsak G., Bates D.W. Detecting adverse events for patient safety research: a review of current methodologies. J. Biomed. Inform. 2003, 36:131-143.
11. Morimoto T., Gandhi T.K., Seger A.C., Hsieh T.C., Bates D.W. Adverse drug events and medication errors: detection and classification methods. Qual. Saf. Health Care 2004, 13:306-314.
12. Bates D.W., Evans R.S., Murff H., Stetson P.D., Pizziferri L., Hripcsak G. Detecting adverse events using information technology. J. Am. Med. Inform. Assoc. 2003, 10:115-128.
13. Handler S.M., Altman R.L., Perera S., Hanlon J.T., Studenski S.A., Bost J.E., et al. A systematic review of the performance characteristics of clinical event monitor signals used to detect adverse drug events in the hospital setting. J. Am. Med. Inform. Assoc. 2007, 14:451-458.
14. Tegeder I., Levy M., Muth-Selbach U., Oelkers R., Neumann F., Dormann H., et al. Retrospective analysis of the frequency and recognition of adverse drug reactions by means of automatically recorded laboratory signals. Br. J. Clin. Pharmacol. 1999, 47:557-564.
15. Evans R.S., Pestotnik S.L., Classen D.C., Bass S.B., Burke J.P. Prevention of adverse drug events through computerized surveillance. Proceedings-the Annual Symposium on Computer Applications in Medical Care 1992, 437-441.
16. Evans R.S., Pestotnik S.L., Classen D.C., Horn S.D., Bass S.B., Burke J.P. Preventing adverse drug events in hospitalized patients. Ann. Pharmacother. 1994, 28:523-527.
17. Raschke R.A., Gollihare B., Wunderlich T.A., Guidry J.R., Leibowitz A.I., Peirce J.C., et al. A computer alert system to prevent injury from adverse drug events: development and evaluation in a community teaching hospital. JAMA 1998, 280:1317-1320.
18. Jha A.K., Laguette J., Seger A., Bates D.W. Can surveillance systems identify and avert adverse drug events? A prospective evaluation of a commercial application. J. Am. Med. Inform. Assoc. 2008, 15:647-653.
19. Reducing and Preventing Adverse Drug Events to Decrease Hospital Costs 2001, Agency for Healthcare Research and Quality, Rockville, MD, AHRQ Publication Number 01-0020.
20. Silverman J.B., Stapinski C.D., Huber C., Ghandi T.K., Churchill W.W. Computer-based system for preventing adverse drug events. Am. J. Health. Syst. Pharm. 2004, 61:1599-1603.
21. Peterson J.F., Williams D.H., Seger A., Gandhi T.K., Bates D.W. Drug-lab triggers have the potential to prevent adverse drug events in outpatients. J. Am. Med. Inform. Assoc. 2002, 9:S39-S40.
22. Hartis C.E., Gum M.O., Lederer J.W. Use of specific indicators to detect warfarin-related adverse events. Am. J. Health. Syst. Pharm. 2005, 62:1683-1688.
23. Chaudhry B., Wang J., Wu S., Maglione M., Mojica W., Roth E., et al. Systematic review: impact of health information technology on quality, efficiency, and costs of medical care. Ann. Intern. Med. 2006, 144:742-752.
24. Longo D.R., Hewett J.E., Ge B., Schubert S., Longo D.R., Hewett J.E., et al. The long road to patient safety: a status report on patient safety systems. JAMA 2005, 294:2858-2865.
25. Shojania K.G., Duncan B.W., McDonald K.M., Watchter R.M. Making Health Care Safer: A Critical Analysis of Patient Safety Practices 2001, Agency for Healthcare Research and Quality, Rockville, MD, p. 43.
26. Institute of Medicine Patient Safety: Achieving a New Standard for Care 2004, The National Academies Press, Washington, DC.
27. Institute of Medicine Crossing the Quality Chasm: A New Health System for the 21st Century 2001, National Academy Press, Washington, DC.
28. Institute of Medicine Preventing Medication Errors 2006, National Academy Press, Washington, DC.
29. Handler S.M., Hanlon J.T., Perera S., Roumani Y.F., Nace D.A., Fridsma D.B., et al. Consensus list of signals to detect potential adverse drug reactions in nursing homes. J. Am. Geriatr. Soc. 2008, 56:808-815.
30. Handler S.M., Hanlon J.T., Perera S., Saul M.I., Fridsma D.B., Visweswaran S., et al. Assessing the performance characteristics of signals used by a clinical event monitor to detect adverse drug reactions in the nursing home. Proc. AMIA 2008, 278-282.
31. Kane-Gill S.L., Weber R.J. Principles and practices of medication errors in the ICU. Crit. Care Clin. 2006, 22:273-290.
32. Kane-Gill S.L., Kowiatek J.G., Weber R.J. A comparison of voluntarily reported medication errors in intensive care and general care units. Qual. Saf. Health Care 2010, 19:55-59.
33. Kane-Gill S.L., Dasta J.F., Schneider P.J., Cook C.H. Monitoring abnormal laboratory values as antecedents to drug-induced injury. J. Trauma 2005, 59:1457-1462.
34. Yount R., Vries J.K., Council C. The Medical Archival System: information retrieval system based on distributed parallel processing. Inf. Proc. Manage. 1991, 27(4).
35. Kramer M.S., Leventhal J.M., Hutchinson T.A., Feinstein A.R. An algorithm for the operational assessment of adverse drug reactions. I. Background, description, and instructions for use. JAMA 1979, 242:623-632.
36. Goh C.L. An approach to the evaluation and documentation of adverse drug reaction. Singapore Med. J. 1989, 30:285-289.
37. Naranjo C.A., Busto U., Sellers E.M., Sandor P., Ruiz I., Roberts E.A., et al. A method for estimating the probability of adverse drug reactions. Clin. Pharmacol. Ther. 1981, 30:239-245.
38. Jones J.K. Definition of events associated with drugs: regulatory perspectives. J. Rheumatol. (Suppl) 1988, 17:14-19.
39. Kane-Gill S.L., Bellamy C.J., Verrico M.M., Saul M.I., Handler S.M., Weber R.J. Evaluating the positive predictive values of antidote signals to detect potential adverse drug reactions (ADRs) in the medical intensive care unit (ICU). Pharmacoepidemiol. Drug Saf. 2009, 18:1185-1191.
40. Kilbridge P.M., Campbell U.C., Cozart H.B., Mojarrad M.G. Automated surveillance of adverse drug events at a community hospital and an academic medical center. J. Am. Med. Inform. Assoc. 2006, 13:372-377.
41. Ferranti J., Horvath M.M., Cozart H., Whitehurst J., Eckstrand J. Reevaluation the safety profile of pediatrics: a comparison of computerized adverse drug event surveillance and voluntary reporting in the pediatric environment. Pediatrics 2008, 121:e1201-e1207.
42. Hwang S.H., Lee S., Koo H.K., Kim Y., Hwang S.-H., Lee S., et al. Evaluation of a computer-based adverse-drug-event monitor. Am. J. Health. Syst. Pharm. 2008, 65:2265-2272.
43. Kane-Gill S.L., Kirisci L., Pathak D.S. Are the Naranjo criteria reliable and valid for determination of adverse drug reactions in the intensive care unit?. Ann. Pharmacother. 2005, 39:1823-1827.
44. Le Gall J.R., et al. A new simplified acute physiology score (SAPS II) based on a European/North American multicenter study. JAMA 1993, 270:2957-2963.
45. Seger A.C., Jha A.K., Bates D.W. Adverse drug event detection in a community hospital utilising computerized medication and laboratory data. Drug Saf. 2007, 30:817-824.
46. Moore C., Li J., Hung C., Downs J., Nebeker J.R. Predictive value of alert triggers for identification of developing adverse drug events. J. Patient Saf. 2009, 5:223-228.
47. Ernst F.R., Levy H., Qualy R.L. Simplified pharmacoeconomics of critical care and severe sepsis. J. Intensive Care Med. 2007, 22:283-293.
48. Goetz M.B., Sayers J. Nephrotoxicity of vancomycin and aminoglycoside therapy separately and in combination. J. Antimicrob. Chemother. 1993, 32:325-334.
49. Moelllering R.C. Vancomycin: a 50-year reassessment. Clin. Infect. Dis. 2006, 42(Suppl. 1):S3-S4.
50. Rybak M.J., Albrecht L.M., Boike S.C., et al. Nephrotoxicity of vancomycin, alone and with an aminoglycoside. J. Antimicrob. Chemother. 1990, 25:679-687.
51. Pauly D.J., Musa D.M., Lestico M.R., Lindstrom M.J., Hetsko C.M. Risk of nephrotoxicity with combination vancomycin-aminoglycoside antibiotic therapy. Pharmacotherapy 1990, 10:378-382.
52. Darko W., Medicis J.J., Smith A., Goharoy R., Lehmann D.F. Cost-effectiveness of pharmacokinetic dosage adjustment of vancomycin to prevent nephrotoxicity. Pharmacotherapy 2003, 23:643-650.
53. Palidino J.A., Sunderlin J.L., Adelman M.H., Singer M.E., Schentag J.J. Observations on vancomycin use in U.S. hospitals. Am. J. Health. Syst. Pharm. 2007, 64:1633-1641.
54. Rybak M., Lomaestro B., Rotschafer J.C., Moellering R., Craig W., Billeter M., et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am. J. Health. Syst. Pharm. 2009, 66:82-98.
55. Lewis K.S., Kane-Gill S.L., Bobek M.B., Dasta J.F. Intensive insulin therapy for critically ill patients. Ann. Pharmacother. 2004, 38:1243-1251.
56. Agency for Healthcare Research and Quality, Triggers and Targeted Injury Detection Systems, 2008, (accessed May 18, 2011). http://www.ahrq.gov/qual/triggers/.
57. Rothschild J.M., Landrigan C.P., Cronin J.W., Kaushal R., Lockley S.W., Burdick E., et al. The Critical Care Safety Study: the incidence and nature of adverse events and serious medical errors in intensive care. Crit. Care Med. 2005, 33:1694-1700.
58. Kopp B.J., Erstad B.L., Allen M.E., Theodorou A.A., Priestley G. Medication errors and adverse drug events in an intensive care unit: direct observation approach for detection. Crit. Care Med. 2006, 34:415-425.